1. Home
  2. SRPT vs TCPC Comparison

SRPT vs TCPC Comparison

Compare SRPT & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRPT
  • TCPC
  • Stock Information
  • Founded
  • SRPT 1980
  • TCPC 2006
  • Country
  • SRPT United States
  • TCPC United States
  • Employees
  • SRPT N/A
  • TCPC N/A
  • Industry
  • SRPT Biotechnology: Pharmaceutical Preparations
  • TCPC Finance/Investors Services
  • Sector
  • SRPT Health Care
  • TCPC Finance
  • Exchange
  • SRPT Nasdaq
  • TCPC Nasdaq
  • Market Cap
  • SRPT N/A
  • TCPC N/A
  • IPO Year
  • SRPT 1997
  • TCPC 2012
  • Fundamental
  • Price
  • SRPT $36.27
  • TCPC $7.20
  • Analyst Decision
  • SRPT Buy
  • TCPC Hold
  • Analyst Count
  • SRPT 23
  • TCPC 4
  • Target Price
  • SRPT $131.09
  • TCPC $7.50
  • AVG Volume (30 Days)
  • SRPT 4.0M
  • TCPC 581.7K
  • Earning Date
  • SRPT 05-06-2025
  • TCPC 05-08-2025
  • Dividend Yield
  • SRPT N/A
  • TCPC 19.50%
  • EPS Growth
  • SRPT N/A
  • TCPC N/A
  • EPS
  • SRPT N/A
  • TCPC N/A
  • Revenue
  • SRPT $2,233,371,000.00
  • TCPC $259,596,996.00
  • Revenue This Year
  • SRPT $64.51
  • TCPC N/A
  • Revenue Next Year
  • SRPT $22.40
  • TCPC N/A
  • P/E Ratio
  • SRPT N/A
  • TCPC N/A
  • Revenue Growth
  • SRPT 59.15
  • TCPC 20.88
  • 52 Week Low
  • SRPT $35.46
  • TCPC $6.27
  • 52 Week High
  • SRPT $173.25
  • TCPC $11.52
  • Technical
  • Relative Strength Index (RSI)
  • SRPT 22.68
  • TCPC 54.07
  • Support Level
  • SRPT $35.46
  • TCPC $6.53
  • Resistance Level
  • SRPT $64.80
  • TCPC $7.12
  • Average True Range (ATR)
  • SRPT 3.78
  • TCPC 0.18
  • MACD
  • SRPT -1.64
  • TCPC 0.08
  • Stochastic Oscillator
  • SRPT 2.76
  • TCPC 85.90

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Share on Social Networks: